Investigational Drug Information for Rintatolimod
✉ Email this page to a colleague
What is the drug development status for Rintatolimod?
Rintatolimod is an investigational drug.
There have been 21 clinical trials for Rintatolimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are AIM ImmunoTech Inc., Roswell Park Cancer Institute, and National Cancer Institute (NCI).
Summary for Rintatolimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,647 |
| WIPO Patent Applications | 1,443 |
| Japanese Patent Applications | 807 |
| Clinical Trial Progress | Phase 2 (2021-11-30) |
| Vendors | 5 |
Recent Clinical Trials for Rintatolimod
| Title | Sponsor | Phase |
|---|---|---|
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | AIM ImmunoTech Inc. | Phase 1/Phase 2 |
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | AstraZeneca BV | Phase 1/Phase 2 |
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | Joachim Aerts, MD PhD | Phase 1/Phase 2 |
Clinical Trial Summary for Rintatolimod
Top disease conditions for Rintatolimod
Top clinical trial sponsors for Rintatolimod
US Patents for Rintatolimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
